<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Leukocytes play an important role in the development of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury </plain></SENT>
<SENT sid="1" pm="."><plain>This study was conducted to ascertain whether synthetic <z:chebi fb="7" ids="16670">peptides</z:chebi> corresponding to the cell- and <z:chebi fb="5" ids="28304">heparin</z:chebi>-binding sequences of fibronectin that disturb leukocyte <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules were effective in neuronal protection after transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="2" pm="."><plain>The authors evaluated the efficacy of <z:chebi fb="7" ids="16670">peptides</z:chebi> on infarction size, <z:mp ids='MP_0002498'>leukocyte infiltration</z:mp> in the ischemic tissue, and neurological outcome in rats subjected to 1 hour of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and 48 hours of reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-one animals were divided into three groups: <z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">transient ischemia</z:e> without treatment (Group I), <z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">transient ischemia</z:e> with administration of vehicle (Group II), and <z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">transient ischemia</z:e> with administration of fibronectin <z:chebi fb="7" ids="16670">peptides</z:chebi> (Group III) </plain></SENT>
<SENT sid="4" pm="."><plain>The mean myeloperoxidase activity (U/g wet wt) in the ischemic area was as follows: Group I, 0.19% +/- 0.05; Group II, 0.21% +/- 0.03; and Group III, 0.08% +/- 0.02 </plain></SENT>
<SENT sid="5" pm="."><plain>The mean size of the infarction as a percentage of the total hemispheric volume was as follows: Group I, 38.35% +/- 1.34%; Group II, 39.21% +/- 2.42%; and Group III, 25.81% +/- 4.87% </plain></SENT>
<SENT sid="6" pm="."><plain>Group III showed a significant decrease in myeloperoxidase activity in the lesion and the infarction size was smaller when compared to Groups I and II (p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>The neurological grade in Group III was significantly better than in Groups I and II at 48 hours after reperfusion (p &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>This study is the first to explore the therapeutic potential of synthetic fibronectin <z:chebi fb="7" ids="16670">peptides</z:chebi> in brain protection after transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, and the results also serve as a basis for studies of important cellular and molecular events that contribute to tissue damage </plain></SENT>
</text></document>